Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.

ABSTRACT:

Background

Bevacizumab combined with chemotherapy produces clinical durable response in 25-30% of recurrent glioblastoma patients. This group of patients has shown improved survival and quality of life. The aim of this study was to investigate changes in gene expression associated with response and resistance to bevacizumab combination therapy.

Methods

Recurrent glioblastoma patients who had biomarker-accessible tumor tissue surgically removed both before bevacizumab treatment and at time of progression were included. Patients were grouped into responders (n = 7) and non-responders (n = 14). Gene expression profiling of formalin-fixed paraffin-embedded tumor tissue was performed using RNA-sequencing.

Results

By comparing pretreatment samples of responders with those o

SUBMITTER: Urup T 

PROVIDER: S-EPMC5395849 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature